摘要
缺血性心肌病作为冠状动脉粥样硬化性心脏病终末期的一种类型,病死率高,预后差。目前临床多采用药物及血运重建治疗缺血性心肌病。与药物治疗相比,血运重建能有效改善心肌供血供氧,恢复心功能,提高患者生存率。现综合近年国内外运用血运重建治疗缺血性心肌病的研究,主要介绍:①经皮冠状动脉介入治疗,裸金属支架,药物涂层支架,生物可降解支架;②经皮冠状动脉介入治疗与冠状动脉搭桥临床作用比较;③治疗性血管再生等治疗方法对该病中远期预后的影响。随着科技的不断进步与医疗水平的不断提高,血运重建的临床效益亦将逐步提高。但无论使用哪一种血运重建方法,均必须与药物结合,控制好血压、血脂、血糖等危险因素,才能最大限度地改善患者的中远期预后。
Ischemic cardiomyopathy,as a type of end-stage coronary heart disease,has high mortality and poor prognosis.Currently in clinic drugs and revascularization are often used as the treatment.Compared with drug therapy,revascularization can effectively improve the myocardial blood and oxygen supply,restore heart function,improve patient survival.Here is mainly to comprehensively introduce the research of revascularization treating ischemic cardiomyopathy in and out of China：①percutaneous coronary intervention（PCI）,bare-metal stents,drug-eluting stents,biodegradable stent;②PCI and coronary artery bypass graft clinical effect comparison;③ medium and long-term outcomes influence of therapeutic vascular regeneration treatments for the disease.Along with the science and technology progress and the medical level increases,revascularization clinical benefit also will gradually improve.However,whichever revascularization method is adopted,it must be combined with drugs,with good control of the risk factors such as blood pressure,blood fat and blood sugar to maximally improve the medium and long-term outcomes.
出处
《医学综述》
2012年第13期2031-2033,共3页
Medical Recapitulate
基金
桂林市科技局2011年立项课题(20110222)
关键词
血运重建
缺血性心肌病
中远期预后
Revascularization
Ischemic cardiomyopathy
Medium and long-term outcomes
